Dana-Farber/Harvard Cancer Center Experimental Therapeutics Clinical Trials Network Site (DF/HCC ETCTN Site) - Incorporation of Mayo Clinic Cancer Center as an Affiliated Center

项目摘要/摘要 此申请是为梅奥诊所癌症中心(MCCC)申请额外资金 Dana-Farber/哈佛癌症中心(DF/HCC)实验治疗附属组织 临床试验网络(ETCTN)领导学术组织(LAO)。由Alex A.博士领导的MCCC调查人员。 Adjei和代表佛罗里达州和亚利桑那州罗切斯特的梅奥诊所的网站已经合并到 DF/CC老挝领导和指导委员会、治理委员会和翻译核心。 此外，他们作为专注于疾病的临床研究人员参与其中，并得到了MCCC的支持 介入放射学、病理学和生物统计学。根据本补编进行的工作将有助于 继续并完成由MCCC领导的针对DNA修复和肿瘤抑制物的ETCTN试验 代谢，以及免疫肿瘤学组合和抗体药物结合物跨实体肿瘤和 恶性血液病。重点将放在MCCC早期职业生涯的持续指导上 研究人员，部分体现在DF/HCC LAO学者对癌症实验的支持 治疗(SCET)计划。作为一名首席执行官，预计在未来一年，MCCC调查人员将 招募至少20名患者参加ETCTN试验，并提交项目团队成员申请(PTMA)和 其他临床试验提案，最终至少有两份批准的意向书(LOI)。MCCC调查人员 还将与DF/CC协调，以确保LAO始终展示至少30%的网络 参与，在以疾病为重点的相关学科中至少开放6项试验，每种疾病有10名登记 一群人。最后，MCCC调查人员还将与DF/HCC合作，增加未成年儿童的入学人数。 通过利用MCCC覆盖的集水区，代表和农村人口参加ETCTN试验 网站。

PROJECT SUMMARY/ABSTRACT This application is being submitted to request additional funds for Mayo Clinic Cancer Center (MCCC) as an Affiliated Organization (AO) to the Dana-Farber/Harvard Cancer Center (DF/HCC) Experimental Therapeutics Clinical Trials Network (ETCTN) Lead Academic Organization (LAO). MCCC investigators, led by Dr. Alex A. Adjei and representing the Mayo Clinic Rochester, Florida and Arizona sites, have been incorporated into the DF/HCC LAO Leadership and Steering Committee, Governance Committee and Translational Core. Additionally, they are participating as disease-focused clinical investigators, with support from MCCC interventional radiology, pathology and biostatistics. Work conducted under this supplement will facilitate the continuation and completion of MCCC-led ETCTN trials that address inhibitors of DNA repair and tumor metabolism, as well as immuno-oncology combinations and antibody drug conjugates across solid tumors and hematologic malignancies. Emphasis will be placed on the continued mentorship of MCCC early career investigators, manifested in part by support afforded by the DF/HCC LAO Scholars in Cancer Experimental Therapeutics (SCET) Program. As an AO, it is anticipated that over the next year, MCCC investigators will enroll a minimum of 20 patients to ETCTN trials and submit Project Team Member Applications (PTMAs) and other clinical trial proposals culminating in at least two approved letters of intent (LOIs). MCCC investigators will also coordinate with DF/HCC to ensure that the LAO consistently demonstrates at least 30% network participation, with at least 6 trials open in relevant disease-focused disciplines with 10 enrollments per disease group. Finally, MCCC investigators will also work with DF/HCC to increase the enrollment of under- represented and rural populations to ETCTN trials by leveraging the catchment area encompassed by MCCC sites.